{
    "clinical_study": {
        "@rank": "9753", 
        "arm_group": {
            "arm_group_label": "BIBW 2992 added to the standard therapy", 
            "arm_group_type": "Experimental", 
            "description": "In part A the maximum tolerated dose (MTD) of oral BIBW 2992 administered continuously added to the standard therapy of Gemcitabine / Cisplatin (Gem/Cis) (administered together on day 1 and 8 of a three-week cycle) will be evaluated in a 2 step dose escalation.\nIn part B (phase Ib) of this study, the MTD cohort may be expanded up to 7 further patients and one or two additional study centers may be recruited.\nDuring Part B dose adjustments, based on individual patient's tolerability, are possible. A dose increase of BIBW 2992 higher than 40 mg daily per os is not permitted."
        }, 
        "brief_summary": {
            "textblock": "An open-label, uncontrolled, multicenter phase I/Ib trial to investigate safety and efficacy\n      of BIBW 2992 added to the standard therapy of Gemcitabine/Cisplatin in chemo-na\u00efve patients\n      with advanced and/or metastatic adenocarcinoma of the biliary tract"
        }, 
        "brief_title": "BIBW 2992 as add-on to Gem/Cis in Advanced Biliary Tract Cancer", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Disease", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasm Metastasis", 
                "Biliary Tract Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "The primary objective is safety and toxicity, including maximum tolerated dose, of BIBW 2992\n      when given as add-on therapy to Gem/Cis."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and female patients aged \u2265 18 years\n\n          -  Signed and dated written informed consent,\n\n          -  Histologically confirmed adenocarcinoma of the gallbladder or intrahepatic bile ducts\n             or extrahepatic bile ducts (metastasized) or histologically proven hepatic metastases\n             of an earlier resected and histologically proven biliary tract cancer or a Klatskin\n             tumour (hilar cholangiocarcinoma)\n\n               -  with pain and biliary obstruction controlled\n\n               -  adequate biliary drainage, no uncontrolled infection\n\n               -  ECOG Performance Status of 0-1\n\n               -  LFTs: bilirubin (total) \u2264 1.5 x ULN, ALT/ AST/ alkaline phosphatase \u2264 3 2.5 x\n                  ULN (\u2264 5 x ULN if liver metastases are present)\n\n               -  No prior systemic treatment i)   previous adjuvant chemotherapy is allowed\n                  (completed \u2265 6 months if containing Gemcitabine or platinum salts); ii)\n                  previous irradiation (external radiotherapy, brachytherapy, chemoembolization)\n                  and PDT are allowed, provided that there is still at least one unidimensionally\n                  measurable target lesion in an untreated area\n\n          -  Resolution of all side effects of prior surgical procedures to CTCAE grade \u2264 1\n             (except for the laboratory values specified below)\n\n          -  At least 4 weeks from any major surgery (at first dose of study drug)\n\n          -  Life expectancy of at least 12 weeks.\n\n          -  Cardiac left ventricular function with resting ejection fraction (LVEF) \u2265 50%\n\n          -  Adequate bone marrow, liver and renal function as assessed by the following\n             laboratory requirements to be conducted within 7 days prior to start of therapy:\n\n               -  Haemoglobin > 10.0 g/dl (=6.2 mmol/l), blood transfusion is allowed\n\n               -  Absolute neutrophil count (ANC) > 1,500/mm3 (=1.5x 109/L)\n\n               -  Platelet count \u2265 100,000/\u03bcl (=100x 109/L)\n\n               -  Total bilirubin \u2264 1.5 times the upper limit of normal\n\n               -  ALT and AST \u2264 2.5 x institutional upper limit of normal (in case of liver\n                  metastases: ALT and AST \u2264 5 x institutional upper limit of normal)\n\n               -  Prothrombin rate > 60% or INR < 1.5\n\n        Main exclusion criteria\n\n          -  Large surgery (except diagnostic biopsy) or smaller surgical procedures, external\n             radiotherapy, brachytherapy, or PDT within 30 days prior to start of treatment.\n\n          -  Other tumor type than adenocarcinoma (e.g. leiomyosarcoma, lymphoma) or a second\n             cancer except in patients with squamous or basal cell carcinoma of the skin or\n             carcinoma in situ of the cervix which has been effectively treated.\n\n          -  History of acute cardiac disease: congestive heart failure > NYHA class 2; active CAD\n             (MI more than 6 months prior to study entry is allowed);\n\n          -  Patients on immunosuppressant therapy or with known HIV infection\n\n          -  Active clinically serious infections (> grade 2 NCI-CTC version 3.0)\n\n          -  History of organ allograft\n\n          -  Pregnant or breast-feeding patients.\n\n          -  Substance abuse, medical, psychological or social conditions that may interfere with\n             the patient's participation\n\n          -  Any condition that is unstable or could jeopardize the safety of the patient and\n             their compliance in the study\n\n          -  Gastrointestinal (GI) tract disease resulting in an inability to take oral medication\n             or a requirement for IV alimentation, prior surgical procedures affecting absorption,\n             or active peptic ulcer disease\n\n          -  History of pre-existing interstitial lung disease (ILD)\n\n          -  Patients with untreated or symptomatic brain metastases.\n\n          -  Persistent Grade 2 or greater neurotoxicity / neuropathy from any cause"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "22", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01679405", 
            "org_study_id": "BIBW 2992"
        }, 
        "intervention": {
            "arm_group_label": "BIBW 2992 added to the standard therapy", 
            "description": "single arm study", 
            "intervention_name": "BIBW 2992", 
            "intervention_type": "Drug", 
            "other_name": "Gemcitabine and Cisplatin"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Cisplatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "metastatic biliary tract cancer", 
        "lastchanged_date": "May 13, 2014", 
        "location": {
            "contact": {
                "email": "Markus.Moehler@unimedizin-mainz.de", 
                "last_name": "Markus Moehler, Prof. Dr. med.", 
                "phone": "0049 6131 17", 
                "phone_ext": "5712"
            }, 
            "facility": {
                "address": {
                    "city": "Mainz", 
                    "country": "Germany", 
                    "zip": "55131"
                }, 
                "name": "I. Medizinische Klinik und Poliklinik der Universit\u00e4tsmedizin"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "1", 
        "official_title": "Open-label, Uncontrolled, Multicenter Phase I/Ib Trial to Investigate Safety and Efficacy of BIBW 2992 and Standard Gemcitabine/Cisplatin in Chemo-na\u00efve Patients With Advanced Biliary Tract Adenocarcinoma", 
        "overall_contact": {
            "email": "Markus.Moehler@unimedizin-mainz.de", 
            "last_name": "Markus Moehler, Prof. Dr. med.", 
            "phone": "0049 6131 17", 
            "phone_ext": "5712"
        }, 
        "overall_official": {
            "affiliation": "University Medical Center of the Johannes Gutenberg-University Mainz", 
            "last_name": "Markus Moehler, Prof. Dr. med.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "In part A the maximum tolerated dose (MTD) of BIBW 2992 administered continuously to the standard therapy of Gemcitabine / Cisplatin (Gem/Cis) (administered together on day 1 and 8 of a three-week cycle) will be evaluated in a 2 step dose escalation.\nSafety and toxicity will be evaluated as described and considered primary for part B of the study.", 
            "measure": "number of adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "No DLT within 21 days after start of therapy; safety and toxicity assessment from time of signing informed consent up to 30 days after end of therapy. Treatment period: up to eight cycles. 12 months follow-up period."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01679405"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Johannes Gutenberg University Mainz", 
            "investigator_full_name": "PD Dr Markus M\u00f6hler", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Progression free survival and overall survival curves will be estimated using the Kaplan-Meier method.\nMedian progression-free survival time and median overall survival time including the 95% confidence intervals will be determined using Kaplan-Meier estimates, if possible.", 
                "measure": "Progression free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Time from start of treatment to first documentation of objective tumour progression or to death due to any cause, whichever occurs first. Estimated time period: up to 76 weeks"
            }, 
            {
                "description": "Progression free survival and overall survival curves will be estimated using the Kaplan-Meier method.\nMedian progression-free survival time and median overall survival time including the 95% confidence intervals will be determined using Kaplan-Meier estimates, if possible.", 
                "measure": "Overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "Time from start of treatment to death due to any cause. Time to last observation will be used if a patient has not died and OS for the patient will be considered censored. Estimated time period: up to 76 weeks"
            }, 
            {
                "description": "Objective response rate and tumour control rate will be analysed by providing absolute and relative frequencies of the categories.\nBest response is defined as the best tumour response (confirmed partial or complete response, stable disease) that is achieved until PD according to Recist 1.1.", 
                "measure": "Objective response rate", 
                "safety_issue": "No", 
                "time_frame": "Objective Response rate is defined as a best response rating of Complete Response (CR) and Partial Response (PR) according to Recist 1.1. Estimated time period: up to 76 weeks"
            }, 
            {
                "description": "Objective response rate and tumour control rate will be analysed by providing absolute and relative frequencies of the categories.\nBest response is defined as the best tumour response (confirmed partial or complete response, stable disease) that is achieved until PD according to Recist 1.1.", 
                "measure": "Tumor control rate", 
                "safety_issue": "No", 
                "time_frame": "Tumour control rate is defined as a best response rating of Complete Response (CR), Partial Response (PR) or Stable Disease (SD) according to Recist 1.1. Estimated time period: up to 76 weeks"
            }
        ], 
        "source": "Johannes Gutenberg University Mainz", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Johannes Gutenberg University Mainz", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}